Palopegteriparatide

DRUG3 trials

Sponsors

Ascendis Pharma A/S

Conditions

Hypoparathyroidism

Phase 3

A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism

RecruitingNCT07706764

Ascendis Pharma A/SHypoparathyroidism

Start: 2026-04-22End: 2031-08-01Target: 12Updated: 2026-07-28

Unknown Phase

A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)

RecruitingNCT07264634

Ascendis Pharma A/SHypoparathyroidism

Start: 2026-03-19End: 2027-08-01Target: 10Updated: 2026-08-07

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

RecruitingNCT07345494

Ascendis Pharma A/SHypoparathyroidism

Start: 2026-02-18End: 2036-01-01Target: 50Updated: 2026-03-02